Arca
Skip to content

NDA 204017: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See NDA 204017's history or Agile Therapeutics, Inc.'s company page.

On Jul 17, 2013, FDA declined to approve NDA 204017 (NDA 204017) from Agile Therapeutics, Inc. in its present form, citing clinical, chemistry, manufacturing and controls (cmc), path forward. The application was later approved.

  • Letter date: Jul 17, 2013
  • Application: NDA 204017
  • Since then: Approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

ClinicalChemistry, manufacturing and controls (cmc)Path forwardHylton v joffe

The Letter

Text from openFDA; FDA's scanned original (PDF) ↗

Dear Ms. Deebo:

We acknowledge receipt of your June 24, 2013, submission to your new drug application (NDA) for Twirla (levonorgestrel and ethinyl estradiol) transdermal delivery system.

For the reasons explained below, we do not consider this submission to be a complete response to our February 13, 2013, action letter. We will not start the review clock until we receive a complete response.

CLINICAL

In our Complete Response letter, we informed you that the two phase 3 studies submitted in your NDA failed to demonstrate acceptable evidence of efficacy. In addition, our review identified substantial problems with study conduct, including low completion rates, and issues with subject follow-up and data collection that limit conclusions and limit our confidence in the study results. One of the deficiencies in the Complete Response letter explicitly stated that you will need to conduct a new phase 3 trial before your NDA may be approved. We do not consider it possible to rely only upon the studies that we have already reviewed to provide adequate evidence of efficacy for your product.

CHEMISTRY, MANUFACTURING AND CONTROLS (CMC)

With regard to your response to Product Quality Deficiencies | and 4:

It is the current policy of the FDA that all transdermal systems be labeled with identifying information including, at a minimum, the name of the product and the strength. Therefore your proposal to seek approval for the product without an identifying label is not acceptable.

With regard to your response to Product Quality Deficiency 2:

The acceptance criterion and justification of the acceptance criterion remain a review issue for cold flow, however at this time, it is noted that the cold flow specification provided on June 24, 2013 appears as:

1. Qualitative Assessment 1: The system can be easily removed from the pouch such that the removal does not alter the physical appearance of the pouch.

Cold Flow! TP103 2. Qualitative Assessment 2: After removal of the release liner, minimal adhesive remains on the release liner and minmal adhesive stringing or balling is observed beyond the perimter of the patch.

3. NMT (4), %

Qualitative Assessment 1 should read: “The system can be easily removed from the pouch such that the removal does not alter the physical appearance of the transdermal system.”

With regard to your response to Product Quality Deficiency 3:

Justification of the specification for excipient assay remains a review issue. We acknowledge the additional in vitro information provided; however, from a cursory review of the information, it appears that the age of the system (utilizing samples from stability studies) is being used to justify the bounds of each excipient acceptance criterion. Because the penetration enhancers work in association with each other, the combined effect of minimum and maximum amounts of all penetration enhancers should be assessed.

With regard to your response to Product Quality Deficiencies 5-8 and Additional CMC and Biopharmaceutics Comments: A cursory review of these responses was performed and we have no additional information to communicate at this time; however, the adequacy of these deficiencies remains a review issue for any future Complete Response submission.

PATH FORWARD

In our Complete Response Letter, we stated that under 21 CFR 314.102(d), you may request a meeting or telephone conference to discuss what steps you need to take before your application may be approved. We note that you did not request such a meeting and instead submitted your June 24, 2013, document without first soliciting feedback from FDA regarding your approach. We strongly recommend that you request a meeting with us prior to another submission so that you can fully understand our concerns described in the Complete Response letter, including our concerns with your completed phase 3 studies and our rationale for the need for a new phase 3 trial. You could consider including information from your June 24, 2013, submission as part of the meeting briefing package together with specific questions to FDA.

If you have any questions, call Charlene Williamson, Regulatory Project Manager, at (301) 796-

1025.

Sincerely, {See appended electronic signature page}

Hylton V. Joffe, M.D., M.M.Sc.

Director

Division of Bone, Reproductive and Urologic Products Office of Drug Evaluation III

Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

HYLTON V JOFFE

07/17/2013

Other Letters on This Application

Record

Company
Agile Therapeutics, Inc.
Application
NDA 204017
Status in openFDA
Approved
Review division
Office of Drug Evaluation III

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.